New immune cell therapy targets Hard-to-Treat liver cancer
Disease control
Recruiting now
This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to at least two other therapies. The treatment uses specially engineered immune cells to attack cancer cells. The goal is to find a safe dose and see if it can shrink tumor…
Phase: PHASE1, PHASE2 • Sponsor: Eureka Therapeutics Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC